Cipla (CPLFY) Cyclically Adjusted PS Ratio: (As of Jul. 11, 2026)


What is Cipla Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cipla  (OTCPK:CPLFY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cipla Cyclically Adjusted PS Ratio Related Terms


Cipla Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Cipla's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Cyclically Adjusted PS Ratio Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.51 3.62 5.54 5.00 3.97

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.13 5.00 4.96 3.97

CPLFY vs ZTS, UTHR: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cipla's Cyclically Adjusted PS Ratio falls into.



Cipla Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cipla's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Cipla's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.861/164.2724*164.2724
=0.861

Current CPI (Mar. 2026) = 164.2724.

Cipla Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.656 105.961 1.017
201609 0.683 105.961 1.059
201612 0.652 105.196 1.018
201703 0.660 105.196 1.031
201706 0.660 107.109 1.012
201709 0.767 109.021 1.156
201712 0.741 109.404 1.113
201803 0.668 109.786 1.000
201806 0.703 111.317 1.037
201809 0.677 115.142 0.966
201812 0.684 115.142 0.976
201903 0.762 118.202 1.059
201906 0.696 120.880 0.946
201909 0.741 123.175 0.988
201912 0.737 126.235 0.959
202003 0.714 124.705 0.941
202006 0.700 127.000 0.905
202009 0.837 130.118 1.057
202012 0.867 130.889 1.088
202103 0.780 131.771 0.972
202106 0.921 134.084 1.128
202109 0.922 135.847 1.115
202112 0.894 138.161 1.063
202203 0.850 138.822 1.006
202206 0.843 142.347 0.973
202209 0.889 144.661 1.010
202212 0.860 145.763 0.969
202303 0.853 146.865 0.954
202306 0.944 150.280 1.032
202309 0.982 151.492 1.065
202312 0.967 152.924 1.039
202403 0.907 153.035 0.974
202406 0.982 155.789 1.035
202409 1.028 157.882 1.070
202412 1.014 158.323 1.052
202503 0.944 157.552 0.984
202506 0.985 159.755 1.013
202509 1.043 162.289 1.056
202512 0.957 163.281 0.963
202603 0.861 164.272 0.861

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.